93206-03-2

Usage

Chemical structure

Contains a triazinone ring with an attached amino group and a complex bis(phenylmethyl)amino)methyl group.

Molecular weight

Not provided, but can be calculated as approximately 420.5 g/mol.

Functional groups

Triazinone ring, amino group, phenyl groups, and a methyl group.

Potential applications

Medicinal chemistry, pharmacology, and materials science due to its unique structure and potential for interaction with biological systems.

Further investigation

Specific properties and potential uses would need to be explored through experimental testing and analysis.
Please note that some information, such as the molecular formula and molecular weight, is inferred based on the given chemical structure. Additional research and experimental data would be required to confirm these values and further explore the compound's properties and applications.

Upstream product

• 2200-97-7 aminoguanidine dihydrogencarbonate 
• 103-49-1 dibenzylamine 
• 2582-30-1 aminoguanidine bicarbonate 
• 93206-02-1 ethyl 3-(dibenzylamino)-2-oxo-propanoate 
• 70-23-5 ethyl Bromopyruvate 

Downstream Products

• 93206-04-3 3-amino-6-(aminomethyl)-1,2,4-triazin-5(4H)-one hydrochloride 
• 936902-00-0 trans-4-[(3-amino-5-oxo-4,5-dihydro[1,2,4]triazin-6-ylmethyl)carbamoyl]cyclohexanecarboxylic acid methyl ester 
• 936890-98-1 OSI-027 
• 936902-01-1 trans-4-(2-amino-4-oxo-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid methyl ester 
• 1260585-94-1 trans-4-(2-amino-5-bromo-4-oxo-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid methyl ester 
• 1260585-95-2 trans-4-(5-bromo-4-oxo-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid methyl ester 
• 1260585-96-3 trans-4-(4-amino-5-bromoimidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid 
• 1187559-63-2 OSI-027 tromethamine 

Relevant academic research and scientific papers

Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors

Although Hsp90 inhibitors can inhibit multiple tumorigenic pathways in cancer cells, their anticancer activity has been disappointingly modest. However, by forcing Hsp90 inhibitors into the mitochondria with mitochondrial delivery vehicles, they were conv

NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF

The present invention relates to novel a imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof

The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivatives, a tautomer thereof, a stereomer and a mixture thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating tankyrase-related diseases comprising the same as active components.COPYRIGHT KIPO 2016

PROCESS FOR SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO-[1,2,4]TRIAZINES

Processes including preparation of trans-4-[(3-amino-5-oxo-4,5-dihydro-[1,2,4]triazin-6-ylmethyl)-carbamoyl]-cyclohexanecarboxylic acid methyl ester, and its conversion to trans-4-(4-amino-5-susbtituted-imidazo[5,1-?][1,2,4]triazin-7-yl)-cyclohexanecarbox